Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

Fast synaptic inhibitory transmission in the CNS is mediated by γ-aminobutyric acid type A (GABAA) receptors. They belong to the ligand-gated ion channel receptor superfamily, and are constituted of five subunits surrounding a chloride channel. Their clinical interest is highlighted by the number of therapeutic drugs that act on them. It is well established that the subunit composition of a receptor subtype determines its pharmacological properties. We have investigated positional effects of two different α-subunit isoforms, α1and α6, in a single pentamer. For this purpose, we used concatenated subunit receptors in which subunit arrangement is predefined. The resulting receptors were expressed inXenopusoocytes and analyzed by using the two-electrode voltage-clamp technique. Thus, we have characterized γ2β2α1β2α1, γ2β2α6β2α6, γ2β2α1β2α6, and γ2β2α6β2α1GABAAreceptors. We investigated their response to the agonist GABA, to the partial agonist piperidine-4-sulfonic acid, to the noncompetitive inhibitor furosemide and to the positive allosteric modulator diazepam. Each receptor isoform is characterized by a specific set of properties. In this case, subunit positioning provides a functional signature to the receptor. We furthermore show that a single α6-subunit is sufficient to confer high furosemide sensitivity, and that the diazepam efficacy is determined exclusively by the α-subunit neighboring the γ2-subunit. By using this diagnostic tool, it should become possible to determine the subunit arrangement of receptors expressedin vivothat contain α1- and α6-subunits. This method may also be applied to the study of other ion channels.

Bibliography

Minier, F., & Sigel, E. (2004). Positioning of the α-subunit isoforms confers a functional signature to γ-aminobutyric acid type A receptors. Proceedings of the National Academy of Sciences, 101(20), 7769–7774.

Authors 2
  1. Frédéric Minier (first)
  2. Erwin Sigel (additional)
References 47 Referenced 97
  1. 10.1146/annurev.ne.17.030194.003033
  2. 10.1002/syn.890210302
  3. 10.1038/385820a0
  4. 10.1523/JNEUROSCI.17-13-05027.1997
  5. 10.1074/jbc.272.24.15346
  6. 10.1111/j.1749-6632.1999.tb11341.x
  7. Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A. N. & Langer, S. Z. (1998) Pharmacol. Rev. 50, 291-313.9647870 / Pharmacol. Rev. (1998)
  8. 10.2174/1568026023393507
  9. 10.1523/JNEUROSCI.12-03-01063.1992
  10. 10.1016/S0021-9258(18)47131-1
  11. 10.1016/S0166-2236(96)80023-3
  12. 10.1097/00001756-199312000-00026
  13. 10.1523/JNEUROSCI.16-17-05415.1996
  14. 10.1523/JNEUROSCI.17-08-02728.1997
  15. 10.1074/jbc.274.15.10100
  16. 10.1074/jbc.M105240200
  17. 10.1074/jbc.M207663200
  18. 10.1016/S0028-3908(02)00036-9
  19. 10.1016/S0028-3908(03)00114-X
  20. 10.1523/JNEUROSCI.18-05-01693.1998
  21. 10.1074/jbc.270.36.21285
  22. Khan, Z. U., Gutierrez, A. & De Blas, A. L. (1996) J. Neurochem. 66, 685-691.8592140 (10.1046/j.1471-4159.1996.66020685.x) / J. Neurochem. (1996)
  23. 10.1523/JNEUROSCI.18-07-02449.1998
  24. 10.1046/j.1471-4159.2003.02135.x
  25. Sigel, E. & Baur, R. (2000) J. Neurochem. 74, 2590-2596.10820222 (10.1046/j.1471-4159.2000.0742590.x) / J. Neurochem. (2000)
  26. 10.1038/sj.bjp.0704121
  27. 10.1016/0014-5793(89)80271-6
  28. 10.1038/346648a0
  29. 10.1016/0169-328X(90)90017-8
  30. 10.1523/JNEUROSCI.10-07-02330.1990
  31. 10.1113/jphysiol.1987.sp016523
  32. Ebert, B., Wafford, K. A., Whiting, P. J., Krogsgaard-Larsen, P. & Kemp, J. A. (1994) Mol. Pharmacol. 46, 957-963.7969086 / Mol. Pharmacol. (1994)
  33. 10.1124/mol.52.6.1150
  34. Korpi, E. R., Kuner, T., Seeburg, P. H. & Lüddens, H. (1995) Mol. Pharmacol. 47, 283-289.7870036 / Mol. Pharmacol. (1995)
  35. Baumann, S. W., Baur, R. & Sigel, E. (2003) J. Neurosci. 23, 11058-11066. / J. Neurosci. (2003)
  36. 10.1124/mol.55.6.993
  37. 10.1016/S0165-6147(00)01646-1
  38. 10.1523/JNEUROSCI.23-27-09004.2003
  39. 10.1016/S0028-3908(02)00151-X
  40. 10.1016/0896-6273(94)90465-0
  41. 10.1016/S0028-3908(01)00158-7
  42. 10.1016/S0028-3908(02)00085-0
  43. 10.1016/S0028-3908(02)00331-3
  44. Saxena, N. C. & Macdonald, R. L. (1996) Mol. Pharmacol. 49, 567-579.8643098 / Mol. Pharmacol. (1996)
  45. 10.1016/S0028-3908(99)00177-X
  46. 10.1523/JNEUROSCI.16-11-03630.1996
  47. 10.1038/nrn731
Dates
Type When
Created 21 years, 3 months ago (May 10, 2004, 9:04 p.m.)
Deposited 1 year, 7 months ago (Jan. 13, 2024, 5:28 a.m.)
Indexed 1 month, 4 weeks ago (July 3, 2025, 12:03 p.m.)
Issued 21 years, 3 months ago (May 10, 2004)
Published 21 years, 3 months ago (May 10, 2004)
Published Online 21 years, 3 months ago (May 10, 2004)
Published Print 21 years, 3 months ago (May 18, 2004)
Funders 0

None

@article{Minier_2004, title={Positioning of the α-subunit isoforms confers a functional signature to γ-aminobutyric acid type A receptors}, volume={101}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.0400220101}, DOI={10.1073/pnas.0400220101}, number={20}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Minier, Frédéric and Sigel, Erwin}, year={2004}, month=may, pages={7769–7774} }